BriLife
(Redirected from
IIBR-100
)
You can help expand this article with text translated from the corresponding article in Hebrew. (November 2021) Click [show] for important translation instructions.
|
SARS-CoV-2 | |
Vaccine type | Viral vector |
---|---|
Clinical data | |
Other names | Brilife |
Routes of administration | Intramuscular |
ATC code |
|
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
BriLife, also known as IIBR-100, is a replication-competent
clinical trials and commercialize the vaccine.[7][8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[9][3]
References
- ^ PMID 33408775.
- PMID 33937326.
- ^ PMID 33422546.
- PMID 34179072.
- ^ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at ClinicalTrials.gov
- PMID 33476760.
- ^ Rabinovitch A, Williams D (12 July 2021). Grebler D (ed.). "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine". Reuters. Retrieved 10 November 2021.
- i24 News. 15 August 2021. Retrieved 10 November 2021.
- PMID 33328475.
External links
- IIBR-100 entry at Stanford Medicine
- Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine
Wikimedia Commons has media related to BriLife.